Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 9, 2016

View Archived Issues

Novo Nordisk offers overview of fourth quarter 2015

Shionogi enters into research collaboration with PeptiDream

New funding supports Affinivax's development of novel pneumococcal vaccine

Olfactory receptors may be a therapeutic target for leukemia

FDA grants afamelanotide orphan drug designation for cutaneous porphyria

Peptide-based antigen-specific immunotherapy prevents anti-FVIII responses

GlaxoSmithKline's gepotidacin shows potential against anthrax

PapGene receives NCI grant to develop ovarian and endometrial cancer tests

Pozen and Tribute combine business and create Aralez Pharmaceuticals

New Ebola virus model developed in rhesus monkeys

Clinical trial data support the use of albutrepenonacog alfa in hemophilia B

BioAxone BioSciences receives fast track grant to support development of BA-1049

Piramal Enterprises discloses GPR120 agonists

Biota starts patient dosing in phase II trial evaluating topical BTA-074 antiviral gel

Bayer Schering Pharma patents GLUT-1 inhibitors

Celgene reports GLP-1 receptor ligands

Institute of Immunology and Experimental Therapy and IPO develop anticancer agents

ViiV Healthcare patent describes anti-HIV compounds

Lifesci Pharmaceuticals describes kallikrein inhibitors

Soricimed Biopharma's SOR-C13 receives U.S. orphan drug designation for ovarian cancer

FDA extends eteplirsen PDUFA date 3 months

Otsuka licenses U.S. rights for atopic dermatitis treatment OPA-15406 to Medimetriks

FDA accepts brexpiprazole sNDA for review

Ferring initiates phase IIIb PRONOUNCE trial of degarelix

FDA clears Sangamo's IND for SB-318

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...